Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)

HIV Clinical Trial

— THIRST  

Official title:

A Pilot Study Of Open-Label Fixed Dose Combination Zidovudine/Lamivudine/Abacavir In HIV-Infected Persons With Tuberculosis In Moshi, Tanzania; Tuberculosis And HIV Immune Reconstitution Syndrome Trial (THIRST)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00851630
• Other study ID #: Pro00013131
• Status: Completed
• Phase: Phase 4
• First received: February 25, 2009
• Last updated: May 2, 2010
• Start date: June 2004
• Est. completion date: September 2007

Study information

• Verified date: May 2010
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardTanzania: National Institute for Medical ResearchTanzania: Food & Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is twofold: (1) to assess the feasibility and safety of fixed dose combination zidovudine/lamivudine/abacavir in HIV infected subjects with tuberculosis in a resource-limited setting, and (2) to assess the impact of delayed versus early initiation strategies for fixed dose combination zidovudine/lamivudine/abacavir on the rate of tuberculosis-associated immune reconstitution inflammatory syndromes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: September 2007
• Est. primary completion date: September 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years and older

Eligibility

Inclusion Criteria:

• HIV Infection is documented by rapid HIV test or any licensed enzyme-linked immunosorbent assay (ELISA) test kit and confirmed with a different sample.

• Men or women admitted to Kibongoto or Marangu Hospitals with (a) recent (within 56 days) smear positive tuberculosis (pulmonary or extrapulmonary,) (b)total lymphocyte count <1,200/mm3, and (c) less than 14 days of antituberculous therapy.

• Antiretroviral naive with the exception of regimens used to prevent mother-to-infant transmission of HIV during pregnancy.

• The following laboratory values obtained within 45 days prior to study entry:

absolute neutrophil count (ANC) >=700/mm³, hemoglobin > 8 g/dL in women; >9 g/dL in men, serum creatinine <= 1.5 times upper limits of normal, AST <5 times upper limits of normal.

• For all women of reproductive potential (who have not reached menopause or undergone hysterectomy, bilateral oophorectomy, or tubal ligation), a negative urine pregnancy test within 48 hours of to study.

• All subjects must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate) and if participating in sexual activity that could lead to pregnancy, the female subject/male partner must use condoms (male or female) without a spermicidal agent.

• Not intending to relocate out of area for the duration of study participation.

• Willingness of subject to adhere to follow up schedule.

• Men and women >= age 13.

• Ability and willingness of subject or legal guardian/representative to give written consent.

Exclusion Criteria:

• Serious illness, other than tuberculosis, that requires systematic treatment and/or hospitalization, until either completion of therapy or clinical stability on therapy in the opinion of the investigator for at least 14 days prior to study entry. Oral and vaginal candidiasis, mucocutaneous herpes simples, and other illnesses which are minor in the opinion of the site investigator are exceptions

• Diagnosis of or suspicion of tuberculosis of the central nervous system.

• > 14 days of antituberculous therapy prior to screening.

• > 28 days of antituberculous therapy for active tuberculosis within the 6 months prior to screening.

• Recent past (within 28 days of study entry) or planned use of corticosteroids.

• Any condition that in the opinion of the investigator would compromise the subject's ability to participate in the study.

• Radiation or systemic chemotherapy within 45 days of entry.

• Any immunomodulator, HIV vaccine, or other investigational therapy within 30 days prior to study entry.

• Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.

• Allergy/sensitivity to any study drugs or their formulations.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV
• HIV Infections
• Immune Reconstitution Inflammatory Syndrome
• Tuberculosis

Intervention

Drug:
• Fixed dose combination zidovudine/lamivudine/abacavir
All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.

Locations

Country	Name	City	State
Tanzania	Kilimanjaro Christian Medical Centre	Moshi

Sponsors (4)

Lead Sponsor	Collaborator
Duke University	GlaxoSmithKline, Kibongoto National Tuberculosis Hospital, Tanzania, Kilimanjaro Christian Medical Centre, Tanzania

Country where clinical trial is conducted

Tanzania, 

References & Publications (1)

Shao HJ, Crump JA, Ramadhani HO, Uiso LO, Ole-Nguyaine S, Moon AM, Kiwera RA, Woods CW, Shao JF, Bartlett JA, Thielman NM. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS R — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Serious Adverse Events (SAEs)	Feasibility and safety of fixed dose combination zidovudine/lamivudine/abacavir in HIV-infected subjects with tuberculosis in a resource-limited setting as assessed by the number of serious adverse events. Serious adverse events included any untoward medical occurrence that resulted in death, was considered life-threatening, required inpatient hospitalization or prolongation of existing hospitalization beyond what was required in the study, or resulted in persistent or resulted in significant disability/incapacity.	104 weeks	Yes
Primary	Tuberculosis-immune Reconstitution Inflammatory Syndrome Events	Tuberculosis-immune reconstitution inflammatory syndrome was defined by the protocol as: a) new persistent fevers (temperature >101.5 degrees Fahrenheit) developing after the initiation of antiretroviral therapy, and not believed to be associated with antiretroviral therapy and without an identifiable source, b) marked worsening or emergence of intrathoracic lymphadenopathy, pulmonary infiltrates or pleural effusions on radiologic examination, or c) worsening or emergence of lymphadenopathy on serial examinations or worsening of other tuberculous lesions.	104 weeks	Yes
Secondary	Plasma HIV Ribonucleic Acid (RNA) Level < 400 Copies/ml	The number of subjects with plasma HIV RNA level <400 copies/ml.	104 Weeks	No
Secondary	HIV RNA Level < 50 Copies/ml	The number of subjects with plasma HIV RNA level <50 copies/ml.	104 Weeks	No